|
|
||||||||
|
|
|||||||||
|
|
Instrumentation & Data Analysis: Data Analysis & ManagementData Analysis and Management Posters |
1 Philips Research, Briarcliff Manor, NY 2 Radiology, Univ. of Washington, Seattle, WA
Abstract No. 2101
Objectives: Partial volume (PV) effects can introduce quantitative biases in PET uptake values. This is important in FDG-based treatment response monitoring where a reduction in tumor size may falsely increase the magnitude of a decrease in metabolic activity. We evaluated the impact of 2 methods of partial volume correction (PVC) in serial FDG scans for patients with head and neck cancer (HNC) and advanced ovarian cancer (AOC).
Methods: FDG PET scans were acquired before and after 3 weeks of chemoradiation on 3 HNC patients, and before and after the third cycle of neoadjuvant chemotherapy on 3 AOC patients. Tumor ROIs based on a region-growing method with a lower threshold of 80% of maximum SUV were generated for each sequential scan. Using a Philips IMALYTICS research workstation, two PV correction methods—Richardson-Lucy deconvolution (RL) and blind deconvolution (BD)—were used to correct mean SUV values within the ROI. Relative percentage (%) changes in mean SUV between serial scans were calculated.
Results: Compared to no PVC, PVC increased mean SUV in pre-tx AOC, post-tx AOC, pre-tx HNC, and post-tx HNC scans by 6.9%, 11.8%, 13.9%, and 13%, respectively, but in these scans RL and BD differed minimally from each other (1%, 0%, 0%, and 0%, respectively). For 2 AOC patients showing partial response, mean SUV reduction was 53.9, 54.5 and 54% (no PVC, RL, and BD, respectively). For an AOC patient with stable disease, no PVC resulted in a much bigger change (10.5%) compared to PVC (RL=1.9%, BD=1.7%). For 3 HNC patients with complete or partial response, mean SUV reduction was 38.6, 40.6 and 40.7% (no PVC, RL, and BD).
Conclusions: Compared to no PVC, PVC resulted in higher mean SUV values for all FDG scans, regardless of the correction algorithm, and showed the greatest difference in a patient with stable disease, indicating a potential role. Additional studies are warranted to better understand the impact of PV effects in this setting.
Research Support: NIH 1R21CA135830, Philips Healthcar
| ||||||||||||||||||||||||||||||||||||||